Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.66 |
| ▸ | DRD3 | P35462 | 18/20 | 0.66 |
| ▸ | HTR2A | P28223 | 12/20 | 0.66 |
| ▸ | HTR1A | P08908 | 4/20 | 0.66 |
| ▸ | DRD4 | P21917 | 4/20 | 0.66 |
| ▸ | HTR2B | P41595 | 4/20 | 0.66 |
| ▸ | HTR2C | P28335 | 3/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bp-14979 SCHEMBL13630506 | 0.91 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Bp-14979 SCHEMBL29730885 | 0.91 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Bp-14979 SCHEMBL24005999 | 0.91 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Bp-14979 SCHEMBL4482277 | 0.91 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL13630394 | 0.86 | DRD2 (0.57) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4490376 | 0.86 | DRD2 (0.57) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4479951 | 0.85 | DRD2 (0.69) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL13629883 | 0.85 | DRD2 (0.69) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4483671 | 0.82 | DRD2 (0.60) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL4496351 | 0.82 | DRD2 (0.65) | DRD2DRD3HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165852-A1 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS | BIOPROJET PHARMA (FR) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165852-A1 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS | DRD3, DRD2, DRD1 | DRD2 2/4885DRD3 1/4885HTR2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.